Ceretas Ltd · ASX:CTS
Ceretas — Investor Presentation (August 2026)
20 slides from Ceretas's investor presentation, Aug 13, 2026
Slide 1: Building the world's first portable, clinic-ready therapeutic ultrasound for Alzheimer's disease
ASX: CTS For personal use only Building the world’s first portable, clinic-ready therapeutic ultrasound for Alzheimer’s disease Investor Presentation - August 2026
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Ceretas Limited and its related entities Australian state or territory legislation (or the law of any similar legislation in any (the “Company”) and is not an offer document. It does not purport to contain all other jurisdiction), or similar provisio
Slide 3: Corporate Overview
Corporate Overview Corporate snapshot (ASX:CTS) Management and Board Shares on issue 71,375,000 Dr Rachel de las Heras CEO and Managing Director For personal use only Previously led ultrasound product development at UQ/QBI Options on issue1 9,580,000 Dr Tony Keating Executive Director Performance ri
Slide 4: Company Overview
Company Overview The First Portable Therapeutic Ultrasound for Alzheimer’s For personal use only No broadly available therapy exists for the 57 million people living with Alzheimer's and related dementias, with 10 million new cases added every year1 A Novel Therapeutic Modality Our device uses ultra
Slide 5: Alzheimer's devastates patients, families and healthcare systems
Alzheimer’s devastates patients, families and healthcare systems For personal use only Alzheimer’s erodes memory, language and reasoning Over 90% of individuals with Alzheimer’s experience behavioural and psychological symptoms of dementia (BPSD)2 – including agitation, apathy, As cognition declines
Slide 6: Alzheimer's is the defining healthcare crisis of the coming decades
Alzheimer’s is the defining healthcare crisis of the coming decades For personal use only Someone develops dementia every Over 83 million global cases of dementia 3.2 seconds1 projected by 20302 $2.8T 1 in 3 older adults dies with Alzheimer’s or Total estimated annual worldwide cost of another demen
Slide 7: Success of current drug therapies is limited
Success of current drug therapies is limited Treating cognition in early-stage Alzheimer’s Treating agitation associated with Alzheimer’s For personal use only Target and remove amyloid-β plaques in the brain Modulate serotonin and dopamine neurotransmission to reduce agitation • Modest clinical ben
Slide 8: Diagnostic ultrasound sees tissue, therapeutic ultrasound changes it
Diagnostic ultrasound sees tissue Therapeutic ultrasound changes it For personal use only Diagnostic Ultrasound Therapeutic Ultrasound Disease modifying potential Preclinical studies have shown ultrasound improves memory and cognition through direct brain stimulation and separately clears amyloid an
Slide 9: One device, two ways to treat Alzheimer's
One device, two ways to treat Alzheimer’s Neuromodulation Blood-brain barrier opening For personal use only Delivers ultrasound stimulation to targeted brain regions, modulating neural activity Uses ultrasound and microbubbles to transiently open by restoring synaptic plasticity and promoting neurog
Slide 10: Clinical Programs
Clinical Programs FIRST-IN-HUMAN SAFETY FEASIBILITY TRIAL PIVOTAL TRIAL DEVICE MODE INDICATION OVERVIEW PRECLINICAL (PHASE 1) (PHASE 2) (PHASE 3) SPONSOR For personal use only Commencing in H2 2026 Neuromodulation Behavioural & Ceretas-led trial to treat Psychological BPSD in mild-moderate Symptoms
Slide 11: Phase 2 Feasibility Trial: Patient Journey
Phase 2 Feasibility Trial: Patient Journey Randomised, double-blind and sham (placebo)-controlled For personal use only Active treatment arm Measure NPI Compare change in Recruit 4 NPI weekly 30 minute (active vs sham) patient with Patient 2 weeks Measure neuromodulation Alzheimer’s randomization tr
Slide 12: Phase 2 Feasibility Trial: Details
Phase 2 Feasibility Trial: Details Two complementary trials targeting two distinct brain regions with two potential outcomes For personal use only Ceretas-led Phase 2 Feasibility Trial Investigator-led Phase 2 Feasibility Trial Sponsor Ceretas The University of Queensland Funding Ceretas, fully-fund
Slide 13: Competitive Landscape
Competitive Landscape Ceretas’s device brings the advantages of focused ultrasound to Alzheimer’s, without the cost and bulk of other approaches For personal use only Essential Tremor, Epilepsy, Brain Alzheimer’s Alzheimer’s Alzheimer’s Alzheimer’s Primary Indication(s) Parkinson’s tumours BPSD & Co
Slide 14: Commercial Model
Commercial Model Device sales into aged care facilities, Biopharma collaboration for drug For personal use only neurology and geriatrician clinics with delivery recurring subscription revenue • Upfront capital equipment sale to the • Over 98% of potential CNS drugs cannot cross clinic or facility th
Slide 15: Milestones & Near-term Catalysts
Milestones & Near-term Catalysts Clinical Development Device & Product Development For personal use only • Advance Ceretas-led Phase 2 feasibility trial in BPSD in mild- • Deliver on the federally funded device development project for moderate Alzheimer’s next-gen device (enhanced single operator us
Slide 16: Contact Details
For personal use only Contact Details Rachel de las Heras Chief Executive Officer & Managing Director [email protected] Tony Keating Executive Director [email protected] Henry Jordan Six Degrees Investor Relations [email protected]
Slide 17: Appendix A. Neuromodulation preclinical data
Appendix A. Neuromodulation preclinical data Neuromodulation restores synaptic plasticity and promotes neurogenesis (improving the brain’s ability to form and repair connections). For personal use only Low-intensity ultrasound restores long-term potentiation and memory in Scanning ultrasound-mediate
Slide 18: Appendix B. Neuromodulation Phase 1 safety data
Appendix B. Neuromodulation Phase 1 safety data Neuromodulation found to be safe and tolerable in humans with promising early efficacy signal in BPSD without needing to clear amyloid and tau For personal use only A pilot safety and tolerability study of scanning ultrasound as a Primary endpoint (saf
Slide 19: Appendix C. BBBO preclinical data
Appendix C. BBBO preclinical data Ultrasound with microbubbles enables removal of amyloid & tau build-up through microglial activation & autophagy (brain’s own protein removal systems) For personal use only Amyloid clearance through microglial activation Tau clearance through autophagy in neurons Sc
Slide 20: Appendix D. Ceretas Management & Board
Appendix D. Ceretas Management & Board For personal use only Dr Rachel de las Heras Dr Tony Keating Al Rey Lunar Vesa Peltonen CO-FOUNDER & CEO EXECUTIVE DIRECTOR CHIEF FINANCIAL OFFICER CHIEF TECHNICAL OFFICER 20 years in medical device Co-founder and CEO of Seasoned finance executive Technical exe